Key Highlights

  • Revenue rose 7.8% to USD 22.2 million in the third quarter ended September 30, 2026, from USD 20.6 million a year earlier, led by contract research and distributor Demand in the Americas and Asia Pacific.
  • GAAP net loss was USD 2.6 million, or USD 0.58 per share, against USD 1.2 million, or USD 0.28, while adjusted loss per share was USD 0.06 versus USD 0.04, management said on the call.
  • Adjusted EBITDA was USD 1.8 million versus USD 2.0 million a year earlier, and adjusted gross Margin of 57.1% was at the low end of the outlook range as lower-margin products and China sales grew.
  • Management lowered full-year adjusted EBITDA growth guidance to negative 1% to 4% from 6% to 10%, while keeping Revenue growth guidance of 3% to 5% for 2026.

Revenue Gains Come With Lower Margin Mix

Harvard Bioscience (NASDAQ:HBIO) filed its Quarterly Report and held its Earnings Call on November 10, 2026. Revenue of USD 22.2 million was up about 8%, with Americas revenue at USD 11.3 million, up 9%, and Asia Pacific at USD 4.6 million, up 29%, including China at USD 2.8 million, up 31%. Europe slipped 5% to USD 6.3 million as management described a weak academic environment. GAAP gross margin was 55.4% against 58.4%, and the filing cites restructuring charges, higher material cost and unfavorable product mix. Operating loss was USD 1.2 million versus Operating Income of USD 0.2 million, while interest expense rose to USD 1.8 million from USD 1.3 million.

Why Adjusted EBITDA Guidance Came Down

The company makes research tools for life science laboratories, including preclinical monitoring devices, electroporation products and organoid technologies. Management said higher volumes of lower-margin legacy products, sales through distribution partners and growth in China pushed margin below plan. It cut its full-year adjusted EBITDA growth outlook to negative 1% to 4%, yet maintained revenue growth of 3% to 5% and adjusted gross margin of 57% to 59%. For the fourth quarter it guided revenue of USD 23.7 million to USD 25.5 million, adjusted gross margin of 59% to 61% and adjusted EBITDA of USD 3.8 million to USD 4.2 million. Operating expenses also rose because salaries, merit pay and Bonus potential were restored this year.

Project Viking Savings and a Thin Cash Position

Cash used in operations over nine months was USD 0.6 million against USD 6.8 million generated a year earlier, which management tied to inventory building, restructuring charges and higher interest. Cash was USD 4.9 million, net Debt was USD 35.1 million and total debt was USD 37.2 million. Principal amortization does not begin until late December 2027 and the Facility matures in December 2029. Project Viking, the Manufacturing consolidation, is on track for completion in the first quarter of 2027, with expected savings of USD 3 million in 2027 and USD 4 million a year after. Management also said it hopes to announce an asset-based revolver. Per share figures reflect a 1-for-10 reverse split completed in March.

Where Things Stand

Because the extra revenue arrived in lower-margin products and channels. Harvard Bioscience (NASDAQ:HBIO) grew sales about 8% on contract research, distributor and China demand, yet adjusted gross margin of 57.1% and adjusted EBITDA of USD 1.8 million slipped, so management lowered its EBITDA growth range while keeping the revenue range. Cash of USD 4.9 million and net debt of USD 35.1 million raise the stakes for the fourth-quarter targets, the Project Viking savings in 2027, and any revolver announcement.